Don't Expect the New Antibiotic Plazomicin to Be Added to Formulary
You'll see the new aminoglycoside, plazomicin (Zemdri, ZEM-dree), promoted for carbapenem-resistant Enterobacteriaceae (CRE).
It works like other aminoglycosides and has the same side effects...nephrotoxicity, ototoxicity, etc.
The difference is that plazomicin isn't as affected by aminoglycoside-modifying enzymes...the most common cause of aminoglycoside resistance to E. coli and other Enterobacteriaceae.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals